Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis.

Oncotarget · 2017 · PMC5722584 · PMID 29228632

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.1100

boldest claim

The sentences

showed a trendP = 0.07so close (0.05 < p ≤ 0.1)

Patients with high baseline plasma VEGF-A levels showed a trend toward improved OS (HR = 0.72, 95% CI, 0.57–0.93), compared with those with low VEGF-A levels (HR = 1.01 [95% CI, 0.77–1.31], interaction P = 0.07).

also in 53,322 other papers

a positive trendP = 0.11not close (p > 0.1)

Regorafenib group showed significantly longer PFS than placebo group with no significant increase of severe toxicities, but OS improvement of regorafenib showed only a positive trend (5.8 vs. 4.5 months, HR = 0.74, P = 0.11).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.